Open Access Short Communication

The “Three-Combined Evidence System” Of Traditional Chinese Medicine in AI Era

Feijuan Huang1*, Jieren Liu1,2, Sadaruddin Chachar3, Zaid Chachar4

1Shenzhen Second People’s Hospital, Shenzhen, China.

2Shenzhen Technology University, China.

3Shenzhen Wemed Medical Equipment Co., Ltd.

4The Chinese University of Hong Kong, Shenzhen, China.

Corresponding Author

Received Date:March 10, 2026;  Published Date:March 25, 2026

Short Communication

Traditional Chinese Medicine’s “syndrome differentiation and treatment” is essentially individualized precision medicine based on multidimensional features [1,2] such as tongue images and clinical indicators [3], pulse signals [4] and multi-omics [5] in the study of syndrome differentiation and biological basis. The National Administration of Traditional Chinese Medicine lunched “threecombined evidence system” [6], which refers to an integrated evaluation framework for new Traditional Chinese Medicine (TCM) drugs, combining:
1. Human use experience-based on long-term clinical practice data regarding efficacy and safety;
2. Clinical trials-following modern evidence-based medicine standards, such as Randomized Controlled Trials (RCT)
3. Basic research-encompassing the study of active components/leads, mechanisms, pharmacokinetics and pharmacodynamics.

irispublishers-openaccess-complementary-alternative-medicine

However, how to scientifically transform the massive fragmented “Human Use Experience (HUE)” into evidence-based proof that meets modern regulatory requirements, and establish the intrinsic mapping rules between “syndrome” and “precision biomarkers,” is currently a bottleneck/great opportunity in the modernization and development of Traditional Chinese Medicine. Using AI to perform cross-temporal and spatial representation alignment of millennia-old classical medical texts and clinical practice (HUE), traditional experience can be deconstructed into computable digital twin models, enabling reverse discovery and prospective simulation prediction from retrospective experience to translational medicine.

Funding

This paper is supported by Shenzhen Stable Support Project for Universities (20231127194506001) and Guangdong Province General Colleges and Universities Innovation Project (2024KTSCX055).

Citation
Keywords
Signup for Newsletter
Scroll to Top